Jianqin Wan

Shandong University — China

Materials Science · Physical Sciences

20h-index1.6kcitations65works14.72yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Nanoparticle-Based Drug Delivery(47), Nanoplatforms for cancer theranostics(31), RNA Interference and Gene Delivery(15), Cancer Treatment and Pharmacology(14), Supramolecular Self-Assembly in Materials(10)

Publications65 total

Mitochondrial rewiring with small-molecule drug-free nanoassemblies unleashes anticancer immunity
Nature Communications·2024· 17 citedOpen Access
Syringeable Near-Infrared Light-Activated In Situ Immunogenic Hydrogel Boosts the Cancer-Immunity Cycle to Enhance Anticancer Immunity
ACS Nano·2024· 24 cited
Hybrid Homodimeric Prodrug Nanoassemblies for Low-Toxicity and Synergistic Chemophotodynamic Therapy of Melanoma
Biomaterials Research·2024· 3 citedOpen Access
A nanotherapeutic strategy that engages cytotoxic and immunosuppressive activities for the treatment of cancer recurrence following organ transplantation
EBioMedicine·2023· 5 citedOpen Access
Triple‐Combination Immunogenic Nanovesicles Reshape the Tumor Microenvironment to Potentiate Chemo‐Immunotherapy in Preclinical Cancer Models
Advanced Science·2023· 31 citedOpen Access
Figure S2 from Preclinical Evaluation of a Cabazitaxel Prodrug Using Nanoparticle Delivery for the Treatment of Taxane-Resistant Malignancies
2023Open Access
Figure S4 from Preclinical Evaluation of a Cabazitaxel Prodrug Using Nanoparticle Delivery for the Treatment of Taxane-Resistant Malignancies
2023Open Access
Supplementary Methods from Preclinical Evaluation of a Cabazitaxel Prodrug Using Nanoparticle Delivery for the Treatment of Taxane-Resistant Malignancies
2023Open Access
Figure S2 from Preclinical Evaluation of a Cabazitaxel Prodrug Using Nanoparticle Delivery for the Treatment of Taxane-Resistant Malignancies
2023Open Access
Figure S4 from Preclinical Evaluation of a Cabazitaxel Prodrug Using Nanoparticle Delivery for the Treatment of Taxane-Resistant Malignancies
2023Open Access
Supplementary Methods from Preclinical Evaluation of a Cabazitaxel Prodrug Using Nanoparticle Delivery for the Treatment of Taxane-Resistant Malignancies
2023Open Access
Table S1 from Preclinical Evaluation of a Cabazitaxel Prodrug Using Nanoparticle Delivery for the Treatment of Taxane-Resistant Malignancies
2023Open Access
Table S1 from Preclinical Evaluation of a Cabazitaxel Prodrug Using Nanoparticle Delivery for the Treatment of Taxane-Resistant Malignancies
2023Open Access
Data from Preclinical Evaluation of a Cabazitaxel Prodrug Using Nanoparticle Delivery for the Treatment of Taxane-Resistant Malignancies
2023Open Access
Data from Preclinical Evaluation of a Cabazitaxel Prodrug Using Nanoparticle Delivery for the Treatment of Taxane-Resistant Malignancies
2023Open Access
Figure S1 from Preclinical Evaluation of a Cabazitaxel Prodrug Using Nanoparticle Delivery for the Treatment of Taxane-Resistant Malignancies
2023Open Access
Figure S1 from Preclinical Evaluation of a Cabazitaxel Prodrug Using Nanoparticle Delivery for the Treatment of Taxane-Resistant Malignancies
2023Open Access
Figure S3 from Preclinical Evaluation of a Cabazitaxel Prodrug Using Nanoparticle Delivery for the Treatment of Taxane-Resistant Malignancies
2023Open Access
Figure S3 from Preclinical Evaluation of a Cabazitaxel Prodrug Using Nanoparticle Delivery for the Treatment of Taxane-Resistant Malignancies
2023Open Access
Figure S5-S6 from New Generation Nanomedicines Constructed from Self-Assembling Small-Molecule Prodrugs Alleviate Cancer Drug Toxicity
2023Open Access
page 1 of 4Next →

Frequent Co-authors

Hangxiang Wang(50), Liqian Zhou(22), Haiyang Xie(19), Xiaona Chen(15), Zhongjie Lu(14), Lijiang Wang(14), Penghong Song(14), Shusen Zheng(14), Donghai Jiang(13), Jiaping Wu(12), Binbin Xie(11), Tingting Guo(10), Hui Li(10), Lin Zhou(10), Xu Xiao(10), Zhen Li(9), Yiting Qiao(7), Tongyu Li(6), Shusen Zheng(6), Weidong Han(5)